AAIPharma and CML Announce Patrick Walsh’s Resignation as CEO
News Apr 12, 2014
AAIPharma Services Corp. and Cambridge Major Laboratories, Inc. have announced the resignation of Patrick Walsh as Chief Executive Officer together with the appointment of interim CEO, Susan Nestegard.
“Now that the initial foundation, leadership team and process initiatives have been identified, it is time for me to step down,” stated Patrick Walsh. “Over the last 6 months, I was asked to shepherd the two organizations through the first phase of the integration process,” added Mr. Walsh.
Mr. Walsh joined AAIPharma Services Corp. in 2010 as Chief Executive Officer. Since that time, he has led the organization through a number of successful transformational changes, including the 2013 transaction with American Capital, Ltd.
“On behalf of the Board and the employees, I want to thank Pat for his contribution to the development and growth of our Company, and we wish him well in his new endeavors,” commented Ms. Nestegard.
A current member of the Companies’ Boards of Directors, Ms. Nestegard brings over 30 years’ experience in healthcare and research and development.
Ms. Nestegard is the former Executive Vice President and President, Global Healthcare, of Ecolab Inc. She also serves on the boards of directors of American Capital, Ltd. and Hormel Foods Corporation.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
15th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry
Sep 09 - Sep 12, 2018
CE in the Biotechnology & Pharmaceutical Industries: 20th Symposium on the Practical Applications for the Analysis of Proteins, Nucleotides & Small Molecules
Sep 09 - Sep 12, 2018